Navigation Links
EntreMed Reports First Quarter 2009 Financial Results
Date:5/6/2009

ate restructuring effort is substantially complete and the team is focused primarily on the clinical development of ENMD-2076. The Board remains enthusiastic about this exciting compound and believes the recent realignment and continued commitment of the EntreMed team position the Company to pursue and advance prospective partnerships for the ENMD-2076 clinical program."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company focusing primarily on the development of its priority program, ENMD-2076, for the treatment of cancer. ENMD-2076 is an Aurora A and angiogenic kinase inhibitor, which is currently in Phase 1 studies in patients with solid tumors and multiple myeloma. In addition, multiple Phase 1 and 2 clinical trials are ongoing for MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, and ENMD-1198, a novel tubulin-binding agent. The Company also has an approved IND application for Panzem(R) in the treatment of rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results
2. EntreMed Focuses on Development of ENMD-2076
3. EntreMed Reports Clinical Program Progress and Company Update
4. EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
5. EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program
6. EntreMed to Present at the BIO 2008 Annual International Convention
7. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
8. EntreMed Reports First Quarter 2008 Financial Results
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
11. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Allegheny General Hospital’s ... that enables physicians to repair a damaged mitral valve ... MitraClip system, developed by Abbott Vascular , ... progressive and life-threatening condition in which the heart’s mitral ... flow backward from the heart’s left ventricle into the ...
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Iowa, Oct. 30 Barack Obama today,stepped ahead of ... most,critical areas of foreign policy, the effort to eradicate ... this area, he pledged to,increase spending on global HIV/AIDS ... same time increasing overall foreign assistance spending to,$50 billion ...
... radiotherapy to treat breast cancer may, in some cases, ... toxic radiation as does the standard six weeks of ... because the short treatment, known as partial breast irradiation, ... through multiple beams, these beams can pass through the ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ), a ... clinical-stage product candidates for central,nervous system disorders, today ... II clinical trial evaluating VSF-173 in a,clinical model ... examined the effects of VSF-173 on a model ...
... PharmAthene, Inc., a leading,biodefense company specializing in the ... biological terrorism,announced today that it is scheduled to ... 9th Annual Healthcare Conference on Tuesday, November 6, ... Company will be David P.,Wright, President and Chief ...
... vitamin D levels and the overall risk of dying ... 30 in the Journal of the National Cancer ... with a decreased risk of colorectal cancer death. , ... vitamin D can reduce cancer mortality by decreasing cancer ...
... (NASDAQ: ANPI , TSX: ANP), a global ... participate in the CIBC 18th Annual,Healthcare Conference, which ... New York City. Tom Bailey, Angiotech Chief ... a 30-minute break-out session on Monday, November,5, beginning ...
Cached Medicine News:Health News:Obama Pledges Major Expansion of AIDS and Global Poverty Programs 2Health News:Normal tissue not spared in new forms of breast cancer radiotherapy 2Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 2Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 3Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 4Health News:Study finds no connection between vitamin D and overall cancer deaths 2
(Date:10/19/2014)... 2014  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... Dental Supply, Inc., a leading full-service provider of dental ... Schein,s entrance into Japan , the ... to 28 the number of countries in which the ...
(Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
(Date:10/17/2014)... 2014 ... the addition of the  "China Interventional Cardiovascular ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by accelerated ... concept, dietary habit, way of working and ...
Breaking Medicine Technology:Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
... materials contributes to successful outcomes for ... procedures and technique, the materials you ... your patients' outcomes, both short-term and ... Cross-Linked Polyethylene. MARATHON Polyethylene is the ...
Medicine Products: